The FDA has approved Priovant Therapeutics' daily tablet Lisraya (brepocitinib) as the first oral targeted treatment for adults with the rare autoimmune disease dermatomyositis. Supported by Phase 3 VALOR trial data showing significant steroid reduction, the drug carries a standard class-wide boxed warning. Originally licensed from Pfizer in a 2022 spinoff with Roivant Sciences, Lisraya is projected by Leerink Partners to reach $1.8 billion in dermatomyositis sales by 2032.
Lisraya FDA approval dermatomyositis
- ▪The FDA's approval of Lisraya (brepocitinib) grants a broad label for use in all adults with dermatomyositis, regardless of their clinical presentation or prior treatments
- ▪The FDA approved Priovant Therapeutics' daily TYK2/JAK1 inhibitor tablet, Lisraya (brepocitinib), as the first orally available targeted drug for adults with dermatomyositis on August 27, 2026
- ▪Dermatomyositis is a rare autoimmune disease characterized by chronic inflammation, progressive muscle weakness, and skin rashes, affecting approximately one in 100,000 people annually
- ▪Leerink Partners projected that global sales of Lisraya (brepocitinib) for dermatomyositis will reach approximately $49 million in 2027, growing to $1.1 billion in 2029 and $1.8 billion by 2032
VALOR trial steroid reduction
- ▪The FDA approval of Lisraya (brepocitinib) was supported by data from the Phase 3 VALOR study, which showed significantly stronger clinical response than placebo
- ▪In the Phase 3 VALOR study, 45% of dermatomyositis patients taking Lisraya (brepocitinib) stopped steroid treatment entirely, compared to 29% of patients in the placebo group
TYK2/JAK1 inhibitor safety warnings
- ▪Lisraya (brepocitinib) carries a boxed warning for serious infections, malignancy, major adverse cardiovascular events, thrombosis, and death, which Leerink Partners noted is in line with the broader JAK inhibitor class
- ▪Leerink Partners stated that there were no major surprises in the FDA-approved label for Lisraya (brepocitinib)
Cutaneous sarcoidosis Phase 2b
- ▪Priovant Therapeutics is testing Lisraya (brepocitinib) in a Phase 3 study for non-infectious uveitis, with data expected in late 2026, and a Phase 2/3 study for lichen planopilaris
- ▪Priovant Therapeutics is developing Lisraya (brepocitinib) for cutaneous sarcoidosis, with Phase 2b data from the BEACON study in February 2026 showing significant disease activity improvements
Pfizer Roivant licensing deal
- ▪Lisraya (brepocitinib) was originally developed by Pfizer before being licensed to Priovant Therapeutics
- ▪Pfizer licensed Lisraya (brepocitinib) to Priovant Therapeutics as part of a spinoff entity formed with Roivant Sciences in 2022
Story comments
Loading comments…